The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR...
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported that on June 11, 2024, the company granted (i) a non-statutory stock option and (ii) restricted stock units (RSUs)....
Schrödinger is a hybrid biopharma company specializing in physics-based computational chemistry and traditional drug development. The company aims to utilize computational methods to create better dr...
Highlights from analysis from 24/7 Wall Street Analysts Eric Bleeker and Austin Smith can be found below....
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference....
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported that on May 16, 2024, the company granted restricted stock units (RSUs) to newly hired employees....
It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stoc...
Some high-tech biotechs claim to be "TechBio" companies. The term signals the use of an automation-heavy approach to biotech....
Schrödinger, Inc. (NASDAQ:SDGR ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Ramy Farid - President and CEO Geoff Porges - CFO Karen Akinsanya - President R&D, Therap...